Background
There have been few studies done in systemic malignancies to look for differences in molecular profiling in newly diagnosis versus recurrence.
Molecular genetic profiling of ovarian cancer comparing first and recurrent paired tissues revealed significantly high discordance rate (up to 40 %) in some biomarkers which could impact the treatment strategy in recurrent setting.
The difference between treatment naïve and recurrent malignant gliomas profiling is not known.